DRESS syndrome and reversible liver function abnormalities in patients with systemic lupus erythematosus treated with the highly selective JAK-1 inhibitor GSK2586184.
Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden Ronald.van.Vollenhoven@ki.se.
R F
RF
van Vollenhoven
GlaxoSmithKline, Stevenage, Hertfordshire, UK.
M
M
Layton
GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UK.
L
L
Kahl
GlaxoSmithKline, Research Triangle Park, NC, USA.
L
L
Schifano
Claude Huriez Hospital, University of Lille, Lille, France.
E
E
Hachulla
CAICI Institute, Rosario, Santa Fe, Argentina.
D
D
Machado
Claude Huriez Hospital, University of Lille, Lille, France.
D
D
Staumont-Sallé
GlaxoSmithKline, Stockley Park West, Uxbridge, Middlesex, UK.
J
J
Patel
D000328:Adult; D001384:Azetidines / Q000008:administration & dosage / Q000009:adverse effects*; D056486:Chemical and Drug Induced Liver Injury / Q000201:enzymology / Q000209:etiology*; D063926:Drug Hypersensitivity Syndrome / Q000201:enzymology / Q000209:etiology*; D005260:Female; D006801:Humans; D053613:Janus Kinase 1 / Q000037:antagonists & inhibitors; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D016032:Randomized Controlled Trials as Topic; D014230:Triazoles / Q000008:administration & dosage / Q000009:adverse effects*
D001384:Azetidines; C000604226:GSK2586184; D047428:Protein Kinase Inhibitors; D014230:Triazoles; D053613:Janus Kinase 1